]]> The companies plan to use AI to identify potential Covid-19 drug candidates. Credit: SRI International. <\/p>\n
Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates<\/p>\n
Follow the latest updates of the outbreakon ourtimeline.<\/p>\n
Artificial intelligence (AI) technology provider Iktos and research centre SRI International have partnered to discover and develop drugs to treat various viruses, including the novel coronavirus that causes Covid-19 and influenza.<\/p>\n
Iktos will combine its generative modelling technology with SRIs fully automated synthetic chemistry platform called SynFini to design compounds and speed-up the identification of drug candidates.<\/p>\n
The Iktos AI technology leverages deep generative models for the accelerated drug discovery process, made possible via the automatic design of virtual molecules with the required characteristics of a new drug candidate.<\/p>\n
Iktos co-founder and CEO Yann Gaston-Math said: Iktos generative AI technology has proven its value and potential to accelerate drug discovery programs in multiple collaborations with renowned pharmaceutical companies.<\/p>\n
We are eager to apply it to SRIs endonuclease programme and hope our collaboration can make a difference and speed up the identification of promising new therapeutic option for the treatment of Covid-19. <\/p>\n
The SynFini platform is intended to speed-up chemical discovery and development, advancing drugs to the clinic quickly and affordably, said SRI.<\/p>\n
The closed-loop platform is said to automate the design, reaction screening and optimisation (RSO), as well as generation of target molecules.<\/p>\n
SRIs ongoing programme is working towards drugs that can block endonuclease enzymes, known to be prevalent to several viruses.<\/p>\n
These enzymes are associated with viral replication and inhibition of host resistance to infection.<\/p>\n
Covid-19 sequence analysis suggests the presence of an endonuclease that it is nearly 97% genetically similar to the SARS virus.<\/p>\n
According to findings from recent studies, inhibition of the SARS virus endonuclease blocks the virus pathogenesis, said to demonstrate a 100% survival rate in preclinical models.<\/p>\n
Based on research, Covid-19 endonuclease should be a beneficial therapeutic target.<\/p>\n<\/p>\n
<\/p>\n
Read the original here: <\/p>\n
Covid-19 drug development to include AI by Iktos and SRI. - Pharmaceutical Technology<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" ]]> The companies plan to use AI to identify potential Covid-19 drug candidates. Credit: SRI International. Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Follow the latest updates of the outbreakon ourtimeline Continue reading